|
|
| ||
| freemexy |
| ||
| Mylan has launched the first generic version of esmolol hydrochloride
(Brevibloc, Baxter) in the United States for treatment of tachycardia.1
According to Mylan, Esmolol Hydrochloride in Sodium Chloride Injection,
2,500 mg/250 mL (10 mg/mL) Single-Dose Plastic Bag, and 2,000 mg/100 mL
(20 mg/mL) Single-Dose Plastic Bag products are being offered to the
global pharmaceutical company’s institutional customers.wisepoqder Esmolol powder
Mylan’s esmolol hydrochloride products are in the market following FDA approval of an Abbreviated New Drug Application (ANDA). Esmolol Hydrochloride in Sodium Chloride Injection is indicated for the short-term treatment of control of ventricular rate in supraventricular tachycardia, including atrial fibrillation and atrial flutter, and control of heart rate in noncompensatory sinus tachycardia, and control of perioperative tachycardia and hypertension.1 Brevibloc is contraindicated in patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, or overt cardiac failure. The drug should also not be used for treatment of hypertension due primarily to vasoconstriction associated with hypothermia or to prevent tachycardia and/or hypertension.2 In addition, Baxter is cautioning Brevibloc users to carefully monitor during infusion for patients with LV dysfunction, CHF, hypotension, reactive airway disease, and diabetes. Generally, patients with bronchospastic disease should not receive beta blockers, according to Baxter. Due to the relative beta1 selectivity and titratability, esmolol hydrochloride may be used with caution in patients with bronchospastic disease, titrated to the lowest possible dose.2 The most common adverse effect with Brevibloc is hypotension; asymptomatic (25%) and symptomatic (12%), mainly dizziness and diaphoresis. Hypotension usually reverses within 30 minutes of decrease of dose or termination of infusion. Infusion site reactions (8%) have also been reported.2 | ||
| 0 Commentaires | poster un commentaire | Lien Permanent |
| ||
| Cyclofenil powder (2624-43-3)
wisepoqder Cyclofenil powder (INN, USAN, BAN) (brand names Fertodur, Menopax, Ondonid, Ondogyne, Sexovid, others) is a selective estrogen receptor modulator (SERM) used as a gonadotropin stimulant which is or has been marketed in Europe, South Korea, Mexico, and Brazil, among other countries. Cyclofenil powder is a gonadal stimulant and inducer of ovulation. It is used in the treatment of infertility and amenorrhea, but is thought to be less effective than CLOMIPHENE. 05 Cyclofenil powder (2624-43-3) History Cyclofenil powder (INN, USAN, BAN) (brand names Fertodur, Menopax, Ondonid, Ondogyne, Sexovid, others) is a selective estrogen receptor modulator (SERM) used as a gonadotropin stimulant which is or has been marketed in Europe, South Korea, Mexico, and Brazil, among other countries. Cyclofenil was first introduced in 1970 under the brand name Ondogyne in France. Subsequently, it was introduced under the brand names Sexovid in Japan in 1972, Ondonvid in the United Kingdom in 1972, and Fertodur in West Germany in 1972 and Italy in 1974. It was also marketed as Sexovid in Sweden, Neoclym in Italy, and Klofenil in Turkey. Cyclofenil was studied in the 1970s as an agent to induce ovulation in infertile women. It was then investigated as a possible treatment for scleroderma in the 1980s, but was found to be ineffective. Later study of its efficacy in treating Raynaud’s phenomenon in people with scleroderma also found no statistically significant benefit. Cyclofenil powder is a nonsteroidal antiestrogen that is used in the treatment of menstrual disturbances and anovulatory infertility due to hypothalamic-pituitary insufficiency Cyclofenil is an analytical reference standard categorized as an anti-estrogen. 1,2 Anti-estrogens, including cyclofenil, have been used as performance-enhancing drugs in sports doping. This product is intended for research and forensic applications | ||
| 0 Commentaires | poster un commentaire | Lien Permanent |
| Page 214 of 834 |
| Précédent | Suivant |